Page 84 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19

Improvement in infarct region and wall motion, decrease in perfusion defect, increase in systolic pressure/end-systolic volume, but no change in velocity of circumferential fiber Decrease in functional defect, increase in wall movement velocity, perfusion defect improved, increase in systolic pressure/end-systolic volume. Improvement in overall LVEF. Increased regional LVEF and systolic wall motion in the border zone but not infarcted zone

Findings shortening. months. NYHA. PCI.

Follow- Up 3 3 6 4 6 12 6 3 and 6

LVEF Impact Not assessed Yes - improvement Yes - improvement Not assessed Yes - improvement Yes - improvement Yes - improvement No

Outcome Yes Yes Yes Yes Yes Yes Yes Yes

Condition IHD IHD IHD IHD IHD IHD IHD DCM

Delivery Method IC IC IC IC IC IC IC IC

Type of Stem Cell BM MNC BM MNC BM MNC BM MSC [Pas 0] BM MNC BM MNC BM MNC BM MSC

Number of SCs 28 million UNK 2.4 billion 1–2 million UNK UNK 40 million UNK

BMA (mL) 40 UNK 128 15 UNK UNK 40 UNK
Table 2. MSC therapy studies treating cardiac failure.

No. of Patients in Treatment Group 10 34 30 11 9 22 12 12

Type of Study PCT RCT with placebo RCT PCT PCT PCT RCT RCT

Year 2002 2004 2004 2005 2005 2006 2006 2006

Author Strauer et al, Circulation 2002; 106:1913-1918 Chen et al, Chin Med J (Engl) 2004; 117:1443-1448 Wollert et al, Circulation 2004; 364:141-148 Katritsis et al, Catheter Cardiovasc Interv 2005; 65:321-329 Ruan et al, Chinese Med J 2005; 118:1906 Chen et al, J Invasive Cardiol 2006; 18:552-556 Ge et al, Heart 2006; 92:1764-1767 Wang et al, Zhonghua xin xue guan bing za zhi 2006; 34:107-110

www.painphysicianjournal.com S401